Pharma BD Deal Intelligence

Janssen Pharmaceuticals (Johnson & Johnson) / PeptiDream Inc.

2017 · Licensing/Option · $1.1B · Complete

PeptiDream entered a multi-target peptide discovery collaboration with Janssen worth up to $1.15B in preclinical, clinical and commercialization milestones plus undisclosed royalties. Janssen received development and commercialization rights plus an option to peptide-drug conjugate (PDC) applications. Targets cover metabolic and cardiovascular indications. Upfront and research funding undisclosed.

Key facts

• Announced Apr 07, 2017
• Closed Apr 07, 2017
• Deal value $1.1B
• Deal type Licensing/Option
• Therapeutic area Metabolic and cardiovascular disease
• Indications Metabolic and cardiovascular disease
• Key assets Multi-target peptide discovery programs
• Mechanism Peptide Discovery Platform System (PDPS); peptide-drug conjugates

← Browse all deals  ·  How we score deals